Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Pain Management for Cesarean Delivery
NCT02922985Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Countries
- 1
- Sponsor
- The University of Texas Medical Branch at Galveston
- Modality
- Small Molecules
- Conditions
- postoperative pain
01
Overview
Phase 4, randomised, double-blind trial of acetaminophen, bupivacaine hydrochloride 0.75% injection and ketorolac in postoperative pain (2 arms), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoint: Total Opioid Intake in Morphine Milligram Equivalents in the First 48 Hours After Cesarean Delivery. Started Oct 2016; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Multimodal Pain Regimen
IV Acetaminophen + SC Bupivacaine + IM Ketorolac
Placebo Control
Saline Placebo
03
Who it enrols
Women 18-45 years old undergoing elective cesarean delivery with spinal anesthesia.
04
Endpoints
Primary
Total Opioid Intake in Morphine Milligram Equivalents in the First 48 Hours After Cesarean Delivery
Secondary
Time to First Administration of Opioid Pain Medication Post Operatively
Pain Score
Number of Opioid Pain Tablets Remaining on Post-operative Day #7
Hospital Length of Stay
Apgar Score at 5 Minutes
NICU Admission
Need for Respiratory Support
Beyond the preview
Go deeper on NCT02922985.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922985.